Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

15.01
-0.2600-1.70%
Post-market: 15.100.0900+0.60%19:59 EDT
Volume:1.43M
Turnover:21.38M
Market Cap:1.79B
PE:-14.43
High:15.30
Open:15.24
Low:14.70
Close:15.27
Loading ...

Arcutis Biotherapeutics announces new data from two posters at 2025 AAD

TIPRANKS
·
07 Mar

Arcutis Biotherapeutics Inc - Zoryve Cream 0.15% Shows Favorable Safety and Tolerability in Ad Patients

THOMSON REUTERS
·
07 Mar

Arcutis to Highlight Data From Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83Rd American Academy of Dermatology Meeting

THOMSON REUTERS
·
07 Mar

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

GlobeNewswire
·
07 Mar

Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average

Zacks
·
06 Mar

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
06 Mar

Stock Track | Arcutis Biotherapeutics Soars 5.08% on Strong Earnings and Positive Clinical Updates

Stock Track
·
01 Mar

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

GlobeNewswire
·
28 Feb

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.
·
28 Feb

Arcutis Biotherapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
28 Feb

Arcutis Biotherapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
27 Feb

BUZZ-U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences

Reuters
·
27 Feb

BUZZ-Arcutis Biotherapeutics rises on strong sales of skin disease drug

Reuters
·
26 Feb

Strong Buy Rating for Arcutis Biotherapeutics Driven by Zoryve’s Growth and Market Expansion

TIPRANKS
·
26 Feb

Arcutis Biotherapeutics Shares up 5.3% After Narrower Q4 Loss

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve Cream

MT Newswires Live
·
26 Feb

Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Action Date of Oct 13, 2025

THOMSON REUTERS
·
26 Feb

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (Roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $21 From $20

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
26 Feb